Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma

被引：0
|
作者：
Ramachandran, Sharavan [1 ]
Fofaria, Neel [1 ]
Srivastava, Sanjay [1 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [1] On the TRAIL to Overcome BRAF-Inhibitor Resistance
    Geserick, Peter
    Herlyn, Meenhard
    Leverkus, Martin
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (02) : 315 - 318
  • [2] Alternative treatment strategies to overcome MAPK inhibitor resistance in melanoma
    Goetz, Eva
    Rabasha, Bokang
    Garraway, Levi
    CANCER RESEARCH, 2016, 76
  • [3] Overcoming BRAF Inhibitor Resistance in Melanoma
    Smalley, Keiran
    Fedorenko, Inna
    Paraiso, Kim H.
    Flach, Edward
    Anderson, Alexander R.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 910 - 910
  • [4] OVERCOMING BRAF INHIBITOR RESISTANCE IN MELANOMA
    Chan, Xian Yang
    Brassington, Kurt
    Darby, Ian A.
    Piva, Terrence J.
    WOUND REPAIR AND REGENERATION, 2016, 24 (06) : A26 - A26
  • [5] Dual inhibition of CRD-BP and BRAF in BRAF-mutant Melanoma - A novel approach to overcome resistance to BRAF inhibitors
    Kim, T.
    Xu, Y. G.
    Setaluri, V.
    Spiegelman, V.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S107 - S107
  • [6] Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance
    Cerezo, Michael
    Lehraiki, Abdelali
    Millet, Antoine
    Rouaud, Florian
    Plaisant, Magali
    Jaune, Emilie
    Botton, Thomas
    Ronco, Cyril
    Abbe, Patricia
    Amdouni, Hella
    Passeron, Thierry
    Hofman, Veronique
    Mograbi, Baharia
    Dabert-Gay, Anne-Sophie
    Debayle, Delphine
    Alcor, Damien
    Rabhi, Nabil
    Annicotte, Jean-Sebastien
    Heliot, Laurent
    Gonzalez-Pisfil, Mariano
    Robert, Caroline
    Morera, Solange
    Vigouroux, Armelle
    Gual, Philippe
    Ali, Maruf M. U.
    Bertolotto, Corine
    Hofman, Paul
    Ballotti, Robert
    Benhida, Rachid
    Rocchi, Stephane
    CANCER CELL, 2016, 29 (06) : 805 - 819
  • [7] The mechanism and consequences of BRAF inhibitor resistance in melanoma
    Ksenia Golub
    Weiyu Bai
    Zhimeng Zhang
    Huilin Xiao
    Rongyuan Sun
    Junling Shen
    Jianwei Sun
    Genome Instability & Disease, 2023, 4 (5) : 266 - 274
  • [8] Dual HDAC and LSD1 inhibition as a novel strategy to overcome BRAF inhibitor resistance
    Gibson, F.
    Hanly, A.
    Kuang, K.
    Kalin, J.
    Wu, M.
    Cole, P.
    Alani, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S89 - S89
  • [9] Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
    Mak, Gabriel
    Arkenau, Hendrik-Tobias
    Chin, Melvin
    MELANOMA RESEARCH, 2014, 24 (04) : 408 - 412
  • [10] Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
    Martin, Claire A.
    Cullinane, Carleen
    Kirby, Laura
    Abuhammad, Shatha
    Lelliott, Emily J.
    Waldeck, Kelly
    Young, Richard J.
    Brajanovski, Natalie
    Cameron, Donald P.
    Walker, Rachael
    Sanij, Elaine
    Poortinga, Gretchen
    Hannan, Ross D.
    Pearson, Richard B.
    Hicks, Rodney J.
    McArthur, Grant A.
    Sheppard, Karen E.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (10) : 2139 - 2152
12345